Patent – Infringement. Two claims of a patent directed to a dosage regimen for the administration of glatiramer acetate for the treatment of relapsing forms of multiple sclerosis were novel over a piece of prior art, but were also obvious over the prior art. While the two claims were invalid, it was not appropriate for the court to grant an Arrow declaration.